We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

Raymond James Financial Inc. acquired a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the ...

NASDAQ BIIB opened at $139.44 on Friday. The stock has a market cap of $20.41 billion, a PE ratio of 12.46, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen has a fifty-two week low of $128.51 and ...

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth quarter results.

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell.

A weekly summary of insider trading, focusing on notable buy and sell transactions by investors, directors, and executives. The transactions occurred between March 10, 2025, and March 14, 2025. Coca ...